Close

New guidelines for independent batch control of COVID-19 vaccines by EU laboratories

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

Buyout of SpringWorks Brings Back Merck KGaA in the M&A Game

Merck KGaA’s long-standing courtship of SpringWorks Therapeutics has finally...

Roche Looks to Expand its Drug Production in the US

Roche is planning to expand its drug production in...

How Language Barriers Impact Non-Native English Speakers in Healthcare

Language barriers create significant challenges for non-native English speakers...

FDA Approval of AMVUTTRA for ATTR Amyloidosis

Alnylam Pharmaceuticals, Inc., a global leader in RNAi therapeutics,...

Three new Official Control Authority Batch Release (OCABR) guidelines outlining the tests to be performed by the EU’s Official Medicines Control Laboratories (OMCLs) will be part of the independent control of COVID-19 vaccine batches, when they become available in the EU.

The guidelines, which have just been published by the EDQM (European Directorate for the Quality of Medicines & HealthCare), are for:

· Pandemic COVID-19 vaccine (Non-Replicating Chimpanzee Adenovirus-Vectored Vaccine);
· Pandemic COVID-19 vaccine (Non-Replicating Human Adenovirus-Vectored Vaccine);
· Pandemic COVID-19 vaccine (mRNA Vaccine).

As part of OCABR, OMCLs will perform the prescribed tests and make a careful review of the batch release protocol from the manufacturer. COVID-19 vaccines are eligible for EU OCABR according to Article 114 of EU Directive 2001/83/EC, as amended.

Additional guidelines are under development to address other vaccine types which are under development for the COVID-19 pandemic and are intended for the European market (e.g. recombinant protein-based vaccines).

Latest stories

Related stories

Buyout of SpringWorks Brings Back Merck KGaA in the M&A Game

Merck KGaA’s long-standing courtship of SpringWorks Therapeutics has finally...

Roche Looks to Expand its Drug Production in the US

Roche is planning to expand its drug production in...

How Language Barriers Impact Non-Native English Speakers in Healthcare

Language barriers create significant challenges for non-native English speakers...

FDA Approval of AMVUTTRA for ATTR Amyloidosis

Alnylam Pharmaceuticals, Inc., a global leader in RNAi therapeutics,...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back